Literature DB >> 19734413

First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.

Ercole Brusamolino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19734413      PMCID： PMC2738709          DOI： 10.3324/haematol.2009.011320

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  26 in total

1.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

Authors:  Noel Milpied; Eric Deconinck; Fanny Gaillard; Vincent Delwail; Charles Foussard; Christian Berthou; Remy Gressin; Virginie Lucas; Philippe Colombat; Jean-Luc Harousseau
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

3.  Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.

Authors:  Maurizio Martelli; Filippo Gherlinzoni; Amalia De Renzo; Pier Luigi Zinzani; Antonio De Vivo; Maria Cantonetti; Brunangelo Falini; Sergio Storti; Giovanna Meloni; Manuela Rizzo; Anna Lia Molinari; Francesco Lauria; Luciano Moretti; Vito Michele Lauta; Patrizio Mazza; Luciano Guardigni; E Pescarmona; S A Pileri; Franco Mandelli; Sante Tura
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

4.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Authors:  C Haioun; E Lepage; C Gisselbrecht; G Salles; B Coiffier; P Brice; A Bosly; P Morel; C Nouvel; H Tilly; P Lederlin; C Sebban; J Brière; P Gaulard; F Reyes
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

5.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

8.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

Authors:  Herve Tilly; Eric Lepage; Bertrand Coiffier; Michel Blanc; Raoul Herbrecht; Andre Bosly; Michel Attal; Georges Fillet; Catherine Guettier; Thierry Jo Molina; Christian Gisselbrecht; Felix Reyes
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

9.  Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.

Authors:  Umberto Vitolo; Annalisa Chiappella; Emanuele Angelucci; Giuseppe Rossi; Anna Marina Liberati; Maria Giuseppina Cabras; Barbara Botto; Giovannino Ciccone; Gianluca Gaidano; Lorenzo Falchi; Roberto Freilone; Domenico Novero; Lorella Orsucci; Vincenzo Pavone; Enrico Pogliani; Delia Rota-Scalabrini; Flavia Salvi; Anna Tonso; Alessandra Tucci; Alessandro Levis
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glass; Christian Rübe; Markus Loeffler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113
View more
  1 in total

1.  Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire.

Authors:  Aïssata Tolo Diebkilé; Boidy Kouakou; Emeraude N'dhatz; Clotaire D Nanho; N'dogomo Meité; Roméo Ayémou; Mamadou Y Sekongo; Paul Kouéhion; Mozart Konan; Gustave K Koffi; Ibrahima Sanogo
Journal:  Adv Hematol       Date:  2012-05-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.